Is prevention of Type-2 diabetes feasible and efficient in primary care?

King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 Zimmet, 2000, Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?, J. Intern. Med., 247, 301, 10.1046/j.1365-2796.2000.00625.x Mortality. I. American Diabetes Association, red. Diabetes 2001 Vital Statistics, American Diabetes Association, Alexandria, VA, 2001, pp. 77–85. Diabetes complications. I. American Diabetes Association, red. Diabetes 2001 Vital Statistics. American Diabetes Association, Alexandria, VA, 2001, pp. 43–74. Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683 Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care 1998;21(2):296–309. Gerstein, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial 1, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 2006, Effect of ramipril on the incidence of diabetes, N. Engl. J. Med., 355, 1551, 10.1056/NEJMoa065061 Yamaoka, 2005, Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials, Diabetes Care, 28, 2780, 10.2337/diacare.28.11.2780 Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study, Diabetes Care, 20, 537, 10.2337/diacare.20.4.537 Wein, 1999, A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance, Aust. NZ J. Obstet. Gynaecol., 39, 162, 10.1111/j.1479-828X.1999.tb03363.x Lindahl, 1999, Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance, J. Intern. Med., 246, 105, 10.1046/j.1365-2796.1999.00537.x Oldroyd, 2001, Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months, Diabetes Res. Clin. Pract., 52, 29, 10.1016/S0168-8227(00)00244-8 Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med., 344, 1343, 10.1056/NEJM200105033441801 Swinburn, 2001, Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance, Diabetes Care, 24, 619, 10.2337/diacare.24.4.619 Mensink, 2003, Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year, Int. J. Obes. Relat. Metab. Disord., 27, 377, 10.1038/sj.ijo.0802249 Watanabe, 2003, Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers, Diabetes Care, 26, 3209, 10.2337/diacare.26.12.3209 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med., 346, 393, 10.1056/NEJMoa012512 Ramachandran, 2006, The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1), Diabetologia, 49, 289, 10.1007/s00125-005-0097-z Padwal, 2005, A systematic review of drug therapy to delay or prevent type 2 diabetes, Diabetes Care, 28, 736, 10.2337/diacare.28.3.736 Anderson, 2005, Pharmacologic prevention or delay of type 2 diabetes mellitus, Ann. Pharmacother., 39, 102, 10.1345/aph.1E081 Davies, 2004, Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting, Diabet. Med., 21, 403, 10.1111/j.1464-5491.2004.01176.x Sherwin, 2004, Prevention or delay of type 2 diabetes, Diabetes Care, 27, S47 Jermendy, 2005, Can type 2 diabetes mellitus be considered preventable?, Diabetes Res. Clin. Pract., 68, S73, 10.1016/j.diabres.2005.03.010 Prisant, 2004, Preventing type II diabetes mellitus, J. Clin. Pharmacol., 44, 406, 10.1177/0091270004263018 Fontbonne, 1996, The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group, Diabetes Care, 19, 920, 10.2337/diacare.19.9.920 Jarrett, 1979, Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”), Diabetologia, 16, 25, 10.1007/BF00423146 Li, 1999, Effect of metformin on patients with impaired glucose tolerance, Diabet. Med., 16, 477, 10.1046/j.1464-5491.1999.00090.x Yang, 2001, The preventive effect of acarbose and metformin on the IGT population from becomming diabetes mellitus, Chin. J. Endocrinol. Metab., 17, 131 Sartor, 1980, Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation, Diabetes, 29, 41, 10.2337/diab.29.1.41 Keen, 1973, Borderline diabetics and their response to tolbutamide, Adv. Metab. Disord., 2, Suppl-31 Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP–NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP–NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Kaiser, 2003, Acarbose for patients with hypertension and impaired glucose tolerance, JAMA, 290, 3066, 10.1001/jama.290.23.3066-b Kaiser, 2004, Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP–NIDDM data, Diabetologia, 47, 575, 10.1007/s00125-003-1318-y Sawicki, 2004, Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP–NIDDM Trial data, Diabetologia, 47, 976, 10.1007/s00125-004-1410-y Chiasson, 2004, Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP–NIDDM Trial data, Diabetologia, 47, 969, 10.1007/s00125-004-1409-4 Holman, 2000, Possible prevention of type 2 diabetes with acarbose or metformin, Diabet. Med., S1 Holman, 2003, Six-year results from early diabetes intervention trial, Diabet. Med., 20, S15 Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 Durbin, 2004, Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance, Diabetes Obes. Metab., 6, 280, 10.1111/j.1462-8902.2004.0348.x Tuomilehto, 2006, Glucose lowering and diabetes prevention: are they the same?, Lancet, 368, 1218, 10.1016/S0140-6736(06)69421-X Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Heymsfield, 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults, Arch. Intern. Med., 160, 1321, 10.1001/archinte.160.9.1321 Wadden, 2005, Randomized trial of lifestyle modification and pharmacotherapy for obesity, N. Engl. J. Med., 353, 2111, 10.1056/NEJMoa050156 Scheen, 2004, Prevention of type 2 diabetes mellitus through inhibition of the Renin–Angiotensin system, Drugs, 64, 2537, 10.2165/00003495-200464220-00004 Gillespie, 2005, The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes, Diabetes Care, 28, 2261, 10.2337/diacare.28.9.2261 Padwal, 2004, Antihypertensive therapy and incidence of type 2 diabetes: a systematic review, Diabetes Care, 27, 247, 10.2337/diacare.27.1.247 Ingelfiinger, 2006, Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance—is there still hope?, N. Engl. J. Med., 355, 1608, 10.1056/NEJMe068213 Herman, 2005, The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance, Ann. Intern. Med., 142, 323, 10.7326/0003-4819-142-5-200503010-00007 Eddy, 2005, Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes, Ann. Intern. Med., 143, 251, 10.7326/0003-4819-143-4-200508160-00006 Engelgau, 2005, Trying to predict the future for people with diabetes: a tough but important task, Ann. Intern. Med., 143, 301, 10.7326/0003-4819-143-4-200508160-00011 Brandeau, 2005, Modeling complex medical decision problems with the Archimedes model, Ann. Intern. Med., 143, 303, 10.7326/0003-4819-143-4-200508160-00012 Herman, 2006, Managing people at high risk for diabetes, Ann. Intern. Med., 144, 66, 10.7326/0003-4819-144-1-200601030-00018 Eddy, 2006, In response, Ann. Intern. Med., 144, 67, 10.7326/0003-4819-144-1-200601030-00019 Lauritzen, 1999, From science to everyday clinical practice. Need for systematic evaluation of research findings, Scand J. Prim. Health Care, 17, 6, 10.1080/028134399750002818 Lauritzen, 1983, Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics, Lancet, 1, 200, 10.1016/S0140-6736(83)92585-0 Christensen, 2004, Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms, Diabetologia, 47, 1566, 10.1007/s00125-004-1496-2 De, 2003, European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice 7, Eur. Heart J., 24, 1601, 10.1016/S0195-668X(03)00347-6 Engberg, 2002, General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up, J. Fam. Pract., 51, 546